Risk factors
Arvinas (ARVN) risk factors
Item 1A of every Arvinas, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors61 risks7 new15 dropped21 reworded
Arvinas reduced its workforce by 33% in April 2025 and 15% in September 2025 to streamline operations.
Filed Feb 24, 2026 - FY2024 10-K risk factors69 risks
Arvinas faces substantial ongoing financial losses and an accumulated deficit of $1,531.6 million as of December 31, 2024. The company relies entirely on its unproven PROTAC technology platform and key partnerships, such as the Pfizer collaboration for vepdegestrant. Development efforts center on clinical assets including vepdegestrant, ARV-393, ARV-102, and bavdegalutamide.
Filed Feb 11, 2025